REPAIR Impact Fund (Novo Holdings)

The REPAIR Impact Fund, established by Novo Holdings, focuses on replenishing the anti-infective pipeline and combating antimicrobial resistance. Recognizing the critical unmet need caused by the growing threat of antibiotic-resistant infections, the fund invests in companies involved in discovering and early-stage development of novel therapies targeting resistant microorganisms. With over 1.2 million deaths annually attributed to these infections, and projections estimating a higher death toll than cancer by 2050, the REPAIR Impact Fund aims to address one of the world's most pressing medical problems by supporting innovative solutions to strengthen the antibiotic pipeline. The fund targets companies developing innovative approaches to combat antimicrobial resistance, focusing on areas where traditional antibiotics are becoming less effective. It recognizes that the economic impact of unchecked antimicrobial resistance could severely cripple modern medical and surgical advances and reduce global economic output significantly. By investing in early-stage companies, the fund aims to foster the development of groundbreaking therapies that can effectively treat resistant infections and prevent the spread of antimicrobial resistance. The REPAIR Impact Fund's investment strategy prioritizes ventures with strong scientific foundations and the potential to significantly impact the treatment of resistant infections. The fund provides not only financial support but also leverages the expertise and resources of Novo Holdings to assist portfolio companies in navigating the complex landscape of drug development and regulatory approval. Ultimately, the fund's goal is to drive innovation in the anti-infective space and contribute to a future where antimicrobial resistance is effectively managed and controlled.

Anti-infectives, antimicrobial resistance, therapies targeting resistant microorganisms

Core thematic spaces, technologies, and target market segments of interest.